Headline
The latest stories from AHA Today.
The Centers for Disease Control and Prevention released a COVID-19 Viral Testing Tool to help health care providers and individuals understand their COVID-19 testing options and take appropriate next steps.
Only 11% of pregnant women in the Centers for Disease Control and Prevention’s Vaccine Safety Datalink, which includes vaccine safety monitoring data from nine integrated health systems, were fully vaccinated against COVID-19 by May 8, compared with 25% of non-pregnant women, the CDC reported.
A coalition of 13 health care organizations, including the AHA, voiced support for the Accountable Care in Rural America Act, bipartisan legislation that would revise the benchmarking formula for the Medicare Shared Savings Program to ensure participating accountable care organizations have an…
During the COVID-19 pandemic, Milwaukee-based Advocate Aurora Health used its broad resources to ensure adequate supplies and equipment, develop a flexible staffing strategy, create surge predictive models and increase operational efficiencies.
The Senate Finance Committee held a hearing to examine how to improve access to mental health and substance use disorder treatment and address inequities.
More than 1 million Americans selecting a 2021 health plan through the federally facilitated marketplace since April 1 will pay $10 or less per month, the Centers for Medicare & Medicaid Services announced.
The Health Resources and Services Administration awarded 14 organizations grants to hire people to support COVID-19 vaccination and outreach in vulnerable and medically underserved communities.
The Food and Drug Administration added sodium citrate tubes used to collect blood specimens to its device shortage list and recommended health care providers only use the tubes when medically necessary, among other conservation strategies.
The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
Novavax announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy.